Cabaletta Bio

CABA

Market cap $448M

Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds strengthens CABA's financial runway and strategic optionality, supporting a 2H27 BLA timeline.

Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years

Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cabaletta Bio, Inc. is reaffirmed as a Buy despite recent share price volatility, driven by tangible clinical and manufacturing progress. Key catalysts include registrational trials for rese-cel in myositis, promising early data in myasthenia gravis and pemphigus vulgaris, and upcoming SLE and SSc readouts. Rese-cel's outpatient-friendly safety profile, removal of preconditioning, and scalable manufacturing platform position CABA for significant autoimmune market opportunities.

Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV ® study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares' industrialized, automated manufacturing

A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4 refractory patients; next dose cohort actively enrolling Translational data from the first two patients dosed with rese-cel manufactured on the automated Cell Shuttle™ platform showed pharmacokinetic and pharmacodynamic data consistent with other patients dosed in the RESET™ clinical program ASGCT 2026 presentations reinforce Cabaletta's focus on optimizing the patient and physician experience through simplified treatment regimens and scalable reliable manufacturing PHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for patients with autoimmune diseases, today announced new clinical and translational data from the first four patients in the lowest dose cohort in RESET-PV® evaluating preconditioning-free (PC-free) rese-cel (resecabtagene autoleucel) and initial manufacturing and translational data from the first two autoimmune patients treated with rese-cel manufactured using the automated Cellares Cell Shuttle platform in the RESET clinical development program. These data are being presented in separate poster presentations today at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting in Boston, MA.

PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten offering of 51,725,000 shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $150 million. The offering is expected to close on or about May 5, 2026, subject to the satisfaction of customary closing conditions. The financing included participation from Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management and other existing investors, multiple new mutual and sovereign wealth funds and Eli Lilly and Company.

Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry  Initial translational data from the first two patients dosed with rese-cel manufactured by Cellares will be presented at the ASGCT conference in May PHILADELPHIA and SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, and Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a commercial agreement to supply rese-cel (resecabtagene autoleucel) using Cellares' automated Cell Shuttle and through future implementation of Cellares' Cell Q platform.